Substituting tenofovir for stavudine in resource-limited settings: there are challenges ahead.
Johan
J
van Griensven
Lutgarde
L
Lynen
Robert
R
Colebunders
D000225:Adenine / Q000031:analogs & derivatives; D019380:Anti-HIV Agents / Q000009:adverse effects*; D003906:Developing Countries; D004359:Drug Therapy, Combination / Q000379:methods; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates; D018119:Stavudine / Q000009:adverse effects*; D000068698:Tenofovir; D017211:Treatment Failure
D019380:Anti-HIV Agents; D063065:Organophosphonates; D000068698:Tenofovir; D018119:Stavudine; D000225:Adenine